secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0001628280-24-029564
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics Appoints Paul Varki as Chief Legal Officer; Grants Inducement Stock Option
--------------------------------------------------------------------------------

- Paul Varki appointed Chief Legal Officer effective June 24, 2024; 20+ years pharma/biotech legal experience.
- Compensation includes $465K base salary, up to 40% target bonus, $50K sign-on cash award (12-month clawback).
- Inducement option to purchase 150,000 shares vesting over 4 years (1-year cliff); exercise price set at June 24 close.
- Varki previously US General Counsel at Idorsia, SVP/GC at Braeburn/Egalet, and 12 years at GSK.
- Severance: 9 months salary (12 on change in control), pro-rated bonus, accelerated option vesting, 12 months COBRA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024029564/0001628280-24-029564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024029564/avtx-20240624.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-029564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer